From Nasdaq: 2024-04-01 14:38:00

Today’s Zacks Research Daily features 16 major stock reports, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA), and Eli Lilly and Company (LLY). Apple’s revenue and iPhone sales are expected to remain steady in the March quarter, but forex challenges may hurt revenue by 2%. NVIDIA’s growth is driven by AI and accelerated computing demand. Eli Lilly’s revenue growth is powered by new FDA-approved medicines like tirzepatide. Exxon Mobil Corporation (XOM), American Tower Corporation (AMT), and McKesson Corporation (MCK) are also featured in today’s reports.

Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry with a +33.7% return year-to-date. New products like Mounjaro and Zepbound are expected to boost revenue in 2024. The company is making progress in diabetes, obesity, and Alzheimer’s treatments. However, generic competition and pricing pressure pose challenges.

Apple’s shares have struggled, down -11.9% year-to-date. The company expects March quarter revenues to be similar to the year-ago quarter’s figure, but forex headwinds may hurt revenue by 2%. NVIDIA’s stock has outperformed, with a +82.5% return year-to-date. Demand for GPUs is strong, especially in AI and accelerated computing markets.

NVIDIA’s Compute & Networking revenues are gaining from AI and high-performance computing growth. Data center business is expected to benefit from demand for generative AI and large language models. Collaborations with automakers like Mercedes-Benz and Audi are advancing the company’s presence in autonomous vehicles and automotive electronics space. Unfavorable IT spending may impact near-term prospects.



Read more at Nasdaq: Top Stock Reports for Apple, NVIDIA & Eli Lilly